



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BMY 14802

Cat. No.:	HY-153091
CAS No.:	105565-56-8
Molecular Formula:	C ₁₈ H ₂₂ F ₂ N ₄ O
Molecular Weight:	348.39
Target:	Adrenergic Receptor; 5-HT Receptor; Sigma Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (143.52 mM); ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.8703 mL	14.3517 mL	28.7035 mL
		5 mM		0.5741 mL	2.8703 mL	5.7407 mL
		10 mM		0.2870 mL	1.4352 mL	2.8703 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.67 mg/mL (4.79 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BMY 14802 is a sigma-1 receptor (σ ₁ R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM ^{[1][2]} .		
IC ₅₀ & Target	Sigma 1 Receptor	5-HT _{1A} Receptor	α ₁ -adrenergic receptor
In Vivo	BMY 14802 (15 mg/kg; i.p.; single dose) significantly inhibits AIM and decreases dyskinesias, especially in the first hour in rat PD model ^{[1][2]} . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Paquette MA, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. *Psychopharmacology (Berl)*. 2009 Jul;204(4):743-54.

[2]. Paquette MA, et al. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. *Neuroreport*. 2008 Jan 8;19(1):111-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA